<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00058435</url>
  </required_header>
  <id_info>
    <org_study_id>02-122</org_study_id>
    <secondary_id>CDR0000288831</secondary_id>
    <secondary_id>CELLCONTROL-MSKCC-02122</secondary_id>
    <nct_id>NCT00058435</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer</brief_title>
  <official_title>Phase I Trial of the Monoclonal Anti-Idiotype Antibody ACA125 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from monoclonal antibodies combined with tumor cells may make the&#xD;
      body build an immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating&#xD;
      patients who have ovarian epithelial, fallopian tube, or peritoneal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety of varying routes and doses of monoclonal antibody ACA125&#xD;
           anti-idiotype vaccine in patients with ovarian epithelial, fallopian tube, or peritoneal&#xD;
           cancer.&#xD;
&#xD;
        -  Determine an optimal dose and route of this vaccine for a phase II study.&#xD;
&#xD;
        -  Determine the immune response induced by this vaccination in these patients.&#xD;
&#xD;
        -  Determine the time to development of objective tumor response in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are randomized to 1 of 4 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive lower-dose monoclonal antibody ACA125 anti-idiotype vaccine&#xD;
           (MOAB ACA125) intramuscularly (IM) on weeks 0, 2, 4, 6, 10, and 14 in the absence of&#xD;
           disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive higher-dose MOAB ACA125 IM as in arm I.&#xD;
&#xD;
        -  Arm III: Patients receive lower-dose MOAB ACA125 subcutaneously (SC) on weeks 0, 2, 4,&#xD;
           6, 10, and 14 in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm IV: Patients receive higher-dose MOAB ACA125 SC as in arm III. Patients are followed&#xD;
           every 6-12 weeks for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients (10 patients per cohort) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">March 2004</completion_date>
  <primary_completion_date type="Actual">March 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>abagovomab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed ovarian epithelial, fallopian tube, or peritoneal cancer&#xD;
&#xD;
               -  Stage II-IV&#xD;
&#xD;
          -  Initially treated with surgery and at least 1 platinum-based chemotherapy regimen&#xD;
&#xD;
          -  Must have relapsed after initial treatment and completed chemotherapy for recurrent&#xD;
             disease&#xD;
&#xD;
          -  Asymptomatic residual measurable disease on CT scan and/or an elevated CA 125 allowed&#xD;
&#xD;
          -  Complete clinical remission allowed, defined by the following criteria:&#xD;
&#xD;
               -  CA 125 no greater than 35 IU/mL&#xD;
&#xD;
               -  No objective evidence of disease by CT scan&#xD;
&#xD;
               -  Normal physical examination&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2 times normal&#xD;
&#xD;
          -  ALT no greater than 2 times normal&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2 times normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times normal&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No potential for child bearing&#xD;
&#xD;
          -  Human antimurine antibody negative&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No known autoimmune disease (e.g., rheumatoid arthritis or ulcerative colitis)&#xD;
&#xD;
          -  No known immune deficiency (e.g., hypogammaglobulinemia)&#xD;
&#xD;
          -  No known allergy to murine proteins&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 6 weeks since prior interferon&#xD;
&#xD;
          -  At least 6 weeks since prior immunotherapy or biological response modifiers&#xD;
&#xD;
          -  No prior anticancer vaccine&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior cytotoxic or investigational chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 1 week since prior antibiotics&#xD;
&#xD;
          -  No concurrent cyclosporine&#xD;
&#xD;
          -  No other concurrent immunosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Sabbatini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>April 7, 2003</study_first_submitted>
  <study_first_submitted_qc>April 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2003</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2013</last_update_posted>
  <keyword>stage II ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abagovomab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

